Austar Lifesciences Limited
AULSF
$0.02
-$0.05-71.43%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 213.23M | 207.53M | 202.68M | 205.31M | 208.62M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 213.23M | 207.53M | 202.68M | 205.31M | 208.62M |
| Cost of Revenue | 172.41M | 166.75M | 161.78M | 163.99M | 166.74M |
| Gross Profit | 40.82M | 40.78M | 40.90M | 41.32M | 41.88M |
| SG&A Expenses | 30.93M | 31.82M | 32.84M | 32.97M | 33.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.39M | -2.86M | -3.34M | -3.47M | -3.61M |
| Total Operating Expenses | 207.24M | 202.07M | 197.75M | 200.43M | 203.79M |
| Operating Income | 6.00M | 5.45M | 4.93M | 4.87M | 4.83M |
| Income Before Tax | 6.68M | 6.26M | 5.85M | 4.39M | 2.94M |
| Income Tax Expenses | 2.12M | 1.70M | 1.29M | 1.17M | 1.06M |
| Earnings from Continuing Operations | 4.56 | 4.56 | 4.56 | 3.22 | 1.89 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 126.50K | 215.80K | 305.10K | 325.90K | 348.30K |
| Net Income | 4.68M | 4.77M | 4.87M | 3.55M | 2.24M |
| EBIT | 6.00M | 5.45M | 4.93M | 4.87M | 4.83M |
| EBITDA | 10.17M | 9.68M | 9.23M | 9.12M | 9.04M |
| EPS Basic | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Normalized Basic EPS | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| EPS Diluted | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 |
| Normalized Diluted EPS | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 2.05B | 2.05B | 2.05B | 2.05B | 2.05B |
| Average Diluted Shares Outstanding | 2.05B | 2.05B | 2.05B | 2.05B | 2.05B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |